Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1Breast 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

fludarabine phosphate 58Cyclophosphamide 54Epoetin Alfa 43Cyclosporine 42Busulfan 42Peripheral Blood Stem Cell Transplantation 38Mycophenolic Acid 33Darbepoetin alfa 33Antilymphocyte Serum 31Cytarabine 30Whole-Body Irradiation 29Filgrastim 29Methotrexate 26Tacrolimus 25Radiotherapy 25Melphalan 24fludarabine 21Methylprednisolone 17Cord Blood Stem Cell Transplantation 17Granulocyte Colony-Stimulating Factor 13Etoposide 13Daunorubicin 13Rivaroxaban 12apixaban 11Thiotepa 11sargramostim 10epoetin beta 10Dalteparin 10eltrombopag 9Alemtuzumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × paricalcitol × Classical hematology × Clear all
NCT00064376 2018-01-29

Paricalcitol in Treating Patients With Myelodysplastic Syndrome

Cedars-Sinai Medical Center

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡